Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) CEO Anthony G. Quinn purchased 6,218 shares of the company’s stock in a transaction on Friday, May 17th. The stock was acquired at an average price of $6.65 per share, for a total transaction of $41,349.70. Following the completion of the transaction, the chief executive officer now owns 277,152 shares of the company’s stock, valued at approximately $1,843,060.80. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Aeglea Bio Therapeutics stock traded down $0.39 during midday trading on Friday, hitting $6.48. The company’s stock had a trading volume of 84,010 shares, compared to its average volume of 182,536. Aeglea Bio Therapeutics Inc has a 12 month low of $6.31 and a 12 month high of $12.00. The stock has a market cap of $194.74 million, a PE ratio of -3.04 and a beta of 0.89.
Aeglea Bio Therapeutics (NASDAQ:AGLE) last issued its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.04). Equities research analysts anticipate that Aeglea Bio Therapeutics Inc will post -2.19 EPS for the current fiscal year.
AGLE has been the topic of several research reports. JPMorgan Chase & Co. initiated coverage on shares of Aeglea Bio Therapeutics in a research report on Thursday, March 21st. They issued an “overweight” rating and a $14.00 price target on the stock. ValuEngine cut shares of Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 9th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $14.67.
Institutional investors have recently modified their holdings of the business. BNP Paribas Arbitrage SA bought a new stake in Aeglea Bio Therapeutics in the first quarter worth about $32,000. Canada Pension Plan Investment Board acquired a new stake in Aeglea Bio Therapeutics during the 4th quarter worth about $37,000. Meeder Asset Management Inc. raised its holdings in Aeglea Bio Therapeutics by 44.9% during the 4th quarter. Meeder Asset Management Inc. now owns 5,116 shares of the biotechnology company’s stock worth $38,000 after buying an additional 1,585 shares during the period. JPMorgan Chase & Co. raised its holdings in Aeglea Bio Therapeutics by 58.6% during the 1st quarter. JPMorgan Chase & Co. now owns 6,674 shares of the biotechnology company’s stock worth $53,000 after buying an additional 2,467 shares during the period. Finally, Acadian Asset Management LLC acquired a new stake in Aeglea Bio Therapeutics during the 1st quarter worth about $69,000. Hedge funds and other institutional investors own 57.21% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Anthony G. Quinn Acquires 6,218 Shares of Aeglea Bio Therapeutics Inc (AGLE) Stock” was published by Modern Readers and is the property of of Modern Readers. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.modernreaders.com/news/2019/05/17/anthony-g-quinn-acquires-6218-shares-of-aeglea-bio-therapeutics-inc-agle-stock.html.
Aeglea Bio Therapeutics Company Profile
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.
Read More: Balance Sheet
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.